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Abstract Endothelial dysfunction is a predisposing factor
for vascular disease in diabetes, which contributes signif-
icantly to the mortality of diabetic patients. The currently
utilized assessment methods of endothelial function/
dysfunction in humans are associated with various
limitations. Circulating endothelial-derived/associated
markers have been proposed as potential alternatives for
evaluation of the endothelium in condition of vascular
disorders. These indicators include von Willebrand factor,
soluble thrombomodulin, soluble E-selectin, asymmetric
dimethylarginine, tissue plasminogen activator, endothelial
microparticles, circulating endothelial cells and circulating
endothelial progenitor cells. While tentative evidence is
available for most of these biomarkers to serve as reliable
sources of information, their usefulness for routine clinical
applications has not yet been established. Thus, circulating
endothelial markers are currently the subject of intense
research interest and it is anticipated that as more information
becomes available their improved quantification will provide
a suitable diagnostic and prognostic tool for vascular events in
diabetes and related diseases.
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Introduction
Diabetes mellitus is a common chronic metabolic disease
with a growing prevalence rate worldwide. The World
Health Organization (WHO) estimates that, in 2000, at least
171 million people worldwide had diabetes and this figure
is expected to double by 2030 [1]. About 3.2 million deaths
annually are attributable to complications of diabetes.
Depending upon regional prevalence of the disease and
the treatments available, healthcare costs for diabetes are
estimated to range from 2.5%–15% of annual healthcare
budgets [1]. The costs of lost production due to diabetes are
reported to reach 5 times the healthcare costs. The United
States (US) is considered among the top 10 countries in the
world regarding the number of people suffering from
diabetes. According to the American Diabetes Association,
presently, there are nearly 24 million Americans with
diabetes and this figure appears to be significantly higher
than what was reported a decade ago [2]. Unfortunately, of
these individuals, about one-quarter are unaware that they
have the disease.
Several forms of diabetes mellitus are known to exist but
two are recognized as the major ones. Type 1 diabetes is
characterized by an absolute insulin deficiency attributable to
pancreatic insufficiency caused by autoimmune destruction
of β cells [3]. It usually involves children and accounts for
5% to 10% of all diagnosed cases of diabetes in the US. On
the other hand, type 2 diabetes is characterized by insulin
resistance associated with a reduced glucose uptake during
insulin exposure, thus representing a deficiency in the
effectiveness of insulin despite high plasma level of the
hormone. It eventually can lead to an absolute insulin
deficiency due to the progressive dysfunction and failure of
the β cells [4]. Genetic predisposition is considered to be a
key factor for developing type 2 diabetes, but it may
progress with additional risk factors such as obesity [5, 6]
and sedentary lifestyle [7, 8]. Type 2 diabetes usually
manifests itself later in life following slowly developing
metabolic processes that include a phase of glucose
intolerance/prediabetes. Type 2 diabetes accounts for
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approximately 90% to 95% of all diagnosed cases of
diabetes. Increasing incidences of type 2 diabetes is a
major contributory factor to the overall rise in the number
of diabetic patients worldwide.
Both type 1 and type 2 diabetes being associated with
hyperglycemia and related disturbances in body’s metabo-
lism can lead to serious secondary complications, such as
cardiovascular disorders, nephropathy, retinopathy and
neuropathy [9]. Heart disease and stroke are the major
cardiovascular disorders manifested in both types of
diabetes. Diabetes-induced reduced blood flow and
neuropathy in the foot leads to increased risk of foot ulcers
and eventual amputation. Diabetic retinopathy occurring as a
consequence of damage to the small blood vessels in the retina
is a major cause of blindness. The effect of diabetes on the
kidney (i.e., nephropathy) results in kidney failure and death
in 10–20% of people with diabetes [10].
While diabetes is known to be associated with a number
of complications, vascular disease is a prominent feature of
both type 1 and type 2 diabetes. It is reported that as high as
80% of the diabetes mortality is a consequence of this disorder
[11]. Although the reason(s) for diabetic vasculopathy
(angiopathy) is incompletely understood, it is now
established that the vascular endothelium plays a central
role [12]. As described in some details below, the
endothelium is critical for proper functioning of blood
vessels and, hence, target organs. Accordingly, endothelial
dysfunction or injury predisposes diabetic patients to both
microangiopathy and macroangiopathy leading to target
organ damage [12]. Microangiopathy in diabetes is a
hallmark feature of retinopathy, neuropathy and nephropathy
whereas macroangiopathy is more closely linked to
accelerated atherosclerosis. Therefore, maintaining the
function of the endothelium is of prime importance for
healthy vasculature and proper tissue/organ functions.
Determining the status of the endothelium using appropriate
techniques can be instrumental for this assessment.
Although strict glycemic control can lower the incidence
of diabetic complications, this is often difficult to achieve
and is not also sufficient to avert the vascular problem [13].
There is also the question of reliability/sensitivity of the
existing diagnostic tests for glucose [14]. Evidence is also
available indicating that endothelial dysfunction precedes
the development of overt hyperglycemia in patients with
type 2 diabetes [15]. On the other hand, impairment of the
endothelium in type 1 diabetes has been demonstrated to
occur much later after a period of exposure to hyperglycemia
[16]. In view of these observations, endothelial dysfunction,
rather than blood glucose levels, appears attractive for
consideration as a critical early target for detecting vascular
disease in diabetes. However, assessing the status of the
endothelium in human subjects for this application using the
currently utilized functional methods appears problematic for
routine purposes (see below for details). Alternatively, there
are emerging assay methods based on the measurements of
circulating endothelial markers which have the potential to
be developed as viable alternatives for routine human use.
Nonetheless, many of these assays presently are used mainly
for research purposes.
This review article presents a synopsis of currently
available circulating endothelial biomarkers with the
potential to be utilized as convenient and reliable
predictors of endothelial dysfunction in diabetic patients.
To put the review in perspective, it is relevant to briefly
review, as background information, the function of the
endothelium under normal and diabetic conditions, and the
methods that have been used commonly for evaluating
endothelial function/dysfunction in humans.
Background on endothelial function/dysfunction
and its assessment in humans
General remarks on endothelial function
The endothelium is a mono-layer of cells that line the
lumen of all the blood vessels in the body. It provides an
interface between circulating blood and the underlying
vascular smooth muscle. Besides serving as a physical
barrier between the blood and tissues, the endothelium is
involved in multiple other functions, including regulation/
maintenance of vascular tone, coagulation, fibrinolysis, cell
growth and platelet and leukocyte adherence [17, 18]. The
type and location of the blood vessel can determine the
interplay between the endothelium and the vessel. For
instance, endothelial cells in conduit arteries limit
activation of clotting and pro-inflammatory factors, while
they contribute to the regulation of blood flow in
resistance vessels and are involved in the transport and
distribution of nutrients and hormones in precapillary
arterioles [17, 18].
The important role of the endothelium in the regulation
of vascular tone, as a vasodilator, was demonstrated almost
three decades ago by the 1998 Nobel Prize-winner Robert
Furchgott [19]. Its vasodilatory function was shown to be
mediated by what was known as endothelium-derived
relaxing factor (EDRF), which was subsequently identified
as nitric oxide (NO). Nitric oxide is now considered a key
vasodilator substance generated in the vascular endothelium
[20]. To make this possible, endothelial cells constitutively
express the enzyme NO synthase, more specifically NO
synthase-type III (eNOS). For initiation of NO formation,
the first step is activation of the endothelial cells thereby
leading to an increase in intracellular Ca2+concentration.
The eNOS enzyme, with Ca2+/calmodulin binding, then
generates NO using L-arginine as a substrate together with
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reduced nicotinamide adenine dinucleotide phosphate
(NADPH), flavin adenine dinucleotide/mononucleotide
(FAD/FMN), and tetrahydrobiopterin (BH4) as cofactors
[20]. In addition, more recently it was shown that NO itself
can activate eNOS in endothelial cells, suggesting its
involvement in a positive feedback process to further
increase its own release [21]. The NO produced in the
endothelial cells rapidly diffuses into underlying vascular
smooth muscle cells and binds to a heme group of soluble
guanylate cyclase (sGC), resulting in activation of the
enzyme and formation of cyclic GMP (cGMP) [22]. Cyclic
GMP in turn activates a cGMP-dependent protein kinase,
leading to decreased cytosolic Ca2+ in vascular smooth
muscle cells and inhibition of the contractile machinery
followed by vasodilatation [23] (Fig. 1).
Different agonists activating receptor-operated mecha-
nisms in endothelial cells are known to cause the release of
NO. Examples include acetylcholine (Ach), bradykinin,
serotonin and substance P [23, 24]. Nitric oxide is also
released by receptor-independent mechanisms, such as
physical stimuli (e.g., shear stress, ischemia), most likely
independent of the involvement of Ca2+/calmodulin [25].
The release of NO by endothelial cells also takes place
under baseline conditions and this plays a role in the
regulation of blood pressure. Consequently, many studies
have demonstrated that eNOS inhibitors or mechanisms that
impair NO generation elevate blood pressure. Besides
causing vasodilation, NO also mediates many other
functions, which appear to be protective. For example,
NO by inhibiting expression of pro-inflammatory cyto-
kines, chemokines and leukocyte adhesion molecules,
limits vascular recruitment of leukocytes and platelets, thus
limiting associated disorders such as atherosclerosis and
thrombosis [26]. The molecule also inhibits vascular
smooth muscle cell proliferation, which is an early sign of
vasculopathy such as atherosclerosis [26].
It is predictable that endothelial dysfunction can take
place at any level in the vasculature and, as noted above,
this problem is considered a major risk factor for the
development of vascular diseases and target organ damage.
Such a dysfunction occurs with different pathophysiological
conditions including diabetes and related disorders such as
insulin resistance/glucose intolerance/prediabetes [27]. In
the healthy vasculature, there is a balance between
vasodilatation and vasoconstriction. Endothelial NO is a
key factor for vascular tone regulation by inducing
vasodilatation, although prostacyclin and endothelium-
derived hyperpolarizing factor (EDHF) also play similar
roles (albeit to a lesser extent). On the other hand, there
are opposing endothelium-generated factors that promote
vasoconstriction in blood vessels. These factors are
produced in abnormally high amounts under certain
pathological states that affect blood vessels, one being
diabetes. The main factor in this regard is endothelin-1, a
potent vasoconstrictor [28]. Besides causing vasoconstric-
tion on its own, endothelin-1 also augments the vascular
action of other vasoactive contractile substances, such as
norepinephrine, angiotensin II, thromboxane A2 and
prostaglandin H2. Accordingly, the chain of events that
leads from endothelial dysfunction to overt vasculopathy can
be related to an imbalance in the production of these
mediators. This abnormal state may affect the critical role
of the endothelium in overall homeostasis, predisposing it to
pro-angiopathic factors [24, 28].
A number of studies identify impairment of NO
production and/or loss of its biological activity as the
immediate culprit lesion for the dysfunction of the
endothelium [29]. With the availability of suboptimal
concentrations of substrate and/or cofactors for NO synthe-
sis, eNOS becomes uncoupled thereby impairing the
synthesis of the molecule. This situation leads to the
generation of reactive oxygen species (ROS), such as
superoxide anion and hydrogen peroxide, a condition
collectively defined as oxidative stress [30]. The excessive
ROS produced during oxidative stress cannot be completely
scavenged by the available mechanisms which function














Fig. 1 Endothelial cell as a regulator of vascular smooth muscle tone.
Endothelial cells synthesize NO which diffuses into adjacent smooth
muscle cells to activate sGS, generating cGMP. cGMP, through a
reduction in intracellular calcium (Cai
2+), causes relaxation of smooth
muscle cells. Abbreviations: NO: nitric oxide; sGS: soluble guanylate
cyclase; GTP: guanosine triphosphate; cGPM: cyclic GMP; eNOS:
NO synthase-type III; EC: endothelial cell; VSMC: vascular smooth
muscle cell
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scavenger system becomes ineffective, enabling NO to
rapidly react with superoxide to form peroxynitrite, which
further exacerbates the oxidative stress [31, 32].
Effect of diabetes on endothelial function
A large body of clinical and experimental evidence
indicates that both type 1 and type 2 diabetes, depending
upon the severity and duration of the disease, cause
dysfunction of the endothelium, with or without overt
vasculopathy [12, 24, 27]. As an example, in Fig. 2 is
shown impairment of endothelium-dependent relaxation of
aortas from streptozotocin-treated diabetic rats (with type
1-like diabetes) of 14 weeks duration. As stated earlier,
there is also compelling evidence for the hypothesis that
endothelial dysfunction can precede type 2 diabetes, as
evidenced, for example, by the finding of impaired
vascular endothelial responsiveness in subjects with
normal glucose tolerance and with a family history of
diabetes (32). In this regard, endothelial dysfunction may
be a critical early target for preventing overt vascular
disease that may subsequently develop as diabetes ensues.
It is also mentioned that in many cases of type 1 diabetes,
the development of endothelial dysfunction has been
observed to occur after a certain period of exposure to
diabetic milieu [15, 16, 22]. Whichever way it may occur,
endothelial dysfunction, once established, can induce
further alterations in blood vessels that continue to worsen
the disorder. As pointed out above, endothelial dysfunction
linked to diabetes is associated with reduced production of
NO. This effect of the disease may be coupled to the
development of oxidative stress [15, 22, 29, 30]. In addition
to the documentation of biochemical changes, dysfunction
of the endothelium in diabetes has also been shown to be
associated with morphological/structural changes (injury)
of the endothelium, particularly at advanced stages of the
insult. Although it has not been determined systematically,
the literature generally indicates that, depending upon the
type and/or degree of insult, endothelial dysfunction can be
more of local or systemic [22, 33, 34]. The nature of the
dysfunction also determines whether or not it is reversible.
Basic mechanisms underlying endothelial dysfunction
in diabetes
The basic mechanisms underlying endothelial dysfunction
in diabetes and related disorders are very complex and
incompletely understood. However, the mechanisms
described below have been demonstrated to be involved
in this dysfunction. While only a brief account of these
mechanisms is given here, readers are referred to other
available sources for additional information [15, 22, 30].
(a) Mechanisms related to hyperglycemia
Hyperglycemia is a characteristic feature of both type 1
and type 2 diabetes. It plays a pivotal role in diabetes-
associated microvascular complications. Hyperglycemia
and its immediate biochemical sequelae have been shown
to directly affect endothelial function. The example in
Fig. 3 demonstrates that incubation of rat aortas with high
concentration of glucose (45 mM) for 3 h causes inhibition
of endothelium-dependent relaxation.
Glucose transport into endothelial cells occurs by
facilitated diffusion that is not dependent on insulin. This
transport is not also autoregulated in endothelial cells, in
which case an increase in blood glucose concentration leads
to increased intracellular accumulation of glucose and its







Fig. 2 Effect of type 1-like diabetes of 14 weeks duration on
acetylcholine-mediated, endothelium-dependent relaxant responses
of aortas from male streptozotocin-treated rats (n=6 rats/group).







Fig. 3 Effect of high-glucose (45 mM for 3 h) on acetylcholine-
mediated, endothelium-dependent relaxant responses of aortas frommale
rats (n=6 rats/group). *Significantly different from corresponding
control responses (P<0.05)
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Various possibilities have been forwarded to explain how
hyperglycemia causes endothelial dysfunction in diabetes.
Normally, glucose undergoes cellular metabolism through the
glycolytic pathway. Under hyperglycemia four major path-
ways are proposed to affect the function of the endothelium.
Accordingly, hyperglycemia-induced increased generation of
reactive oxygen species (e.g., superoxide) causes exacerbated
oxidative DNA damage and subsequent activation of the poly
(ADP-ribose) polymerase (PARP). This, in turn, results in
PARP-induced addition of ADP-ribose polymers onto the
glyceraldehydes-3 phosphate dehydrogenase (GAPDH)
thereby reducing its activity [15, 22, 30, 38] (Fig. 4).
Consequently, greater substrate availability, upstream of
GAPDH step in the glycolytic pathway, leads to activation
of the four pathways that are briefly described below.
(i) The sorbitol/polyol pathway: In this pathway, excess
glucose is metabolized to sorbitol and fructose by
aldose reductase and sorbitol dehydrogenase. This
pathway may impair endothelial function through two
primary mechanisms: increased osmotic stress and
oxidative stress, although other related mechanisms
are also suggested to be involved [15, 22, 30].
(ii) The hexosamine pathway: In this pathway, fructose-6-
phosphate is converted to fructosamine 6-phosphate by
the enzyme glutamine:fructose 6-phosphate amidotras-
ferase and subsequently into N-acetlyglucosamine.
This pathway has been shown to be involved in the
augmentation of transcription of plasminogen activator
inhibitor-1 (PAI-1) and transforming growth factor
β1 (TGF-β1) and modification of protein kinase C
(PKC) and eNOS [15, 22, 30].
(iii) The protein kinase C (PKC) pathway: The mechanism
responsible for the activation of PKC by hyperglycemia
is related to de novo synthesis of the PKC activator
diacylglycerol (DAG) from a stepwise acylation of
glycerol 3-phosphate and phosphatidic acid. The effect
of PKC activation include inhibition of eNOS activity,
increased endothelin-1 synthesis, basement membrane
thickening (via TGF-β-mediated increased synthesis of
type IV collagen and fibronectin), impaired fibrinolysis
(via tissue plasminogen activator (PAI-1)) and increased
oxidative stress (via NADPH regulation) [15, 22, 30].
(iv) The glycosylation pathway: This pathway involves a
non-enzymatic reaction of glucose and glucose-derived
dicabonyl compounds with the basic amino acids lysine
and arginine in proteins to form advanced glycation end
(AGE) products both extra- and intracellularly. The
formation of AGE products leads to a number of adverse
effects that can affect endothelial cells and other tissues.
These include structural modifications of proteins,
increase in oxidative stress, activation of transcription
factors, increased expression of cytokines and growth





















Fig. 4 Proposed mechanisms by which hyperglycemia and subsequent
overproduction of reactive oxygen species such as superoxide (from
mitochondria and other sources) cause oxidative DNA damage and
activation of PARP. In turn, increased PARP activity causes addition of
ADP-ribose polymer onto the GAPDH resulting in its inhibition.
Inhibition of GAPDH will result in build up of glycolytic intermediates
and their subsequent diversion into and augmentation of the following
four pathways: the sorbitol/polyol, hexosamine, PKC and glycosylation
pathways. Abbreviations: NADPH: reduced nicotinamide adenine
dinucleotide phosphate; eNOS: nitric oxide synthase-type III;
PKC: protein kinase C; ROS: reactive oxygen species; PARP:
poly(ADP-ribose) polymerase; GAPDH: glyceraldehydes-3-
phosphate dehydrogenase; AGEs: advanced glycation end (products)
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(b) Mechanisms related to action of insulin
Insulin is a vasoactive hormone which can increase
blood flow through processes involving binding to insulin
receptors on endothelial cell membrane. By this process,
insulin increases the production of NO and induces
endothelium-dependent vasorelaxation, although the
molecular pathway has not yet been fully elucidated.
However, it has been suggested to involve the activation of
the intracellular enzymes phosphatidylinositol-3-kinase
(PI3K) and Akt, which ultimately lead to phosphorylation
and activation of eNOS. Besides the generation of NO,
insulin, via another pathway (mitogen-activated protein
kinase (MAPK) pathway), causes the release of endothelin-1
by endothelial cells, and growth and migration of vascular
smooth muscle cells [15, 22, 27, 39, 40] (Fig. 5).
The vasodilator action of insulin is impaired under
conditions of insulin-resistance, more notably prediabetes,
type 2 diabetes, obesity and hypertension. It is also decreased
by mediators closely associated with insulin-resistance,
namely tumor necrosis factor-α (TNF-α), non-esterified
fatty acids (NEFAs) and an impaired NO-dependent action
[15, 22]. Similarly, when there is an absolute lack or
impairment of insulin production as in type 1 diabetes,
effects mediated by insulin per se in endothelial cells (and
elsewhere) will be lacking, potentially shifting the balance
in favor of vasoconstriction. In support of impaired
vascular relaxation in insulin resistance, endothelin-1
released from the endothelium by increased plasma insulin
level has been suggested to have a contributory role [22, 39].
Another important aspect of insulin resistance/type 2
diabetes is the consideration that it is linked to elevated
plasma free fatty acids which can generate ROS via
mitochondrial oxidation [18, 23, 26]. The ROS produced
subsequently undergo similar metabolic pathways as shown
for hyperglycemia (Fig. 4). However, unlike the role of
hyperglycemia, this mechanism is proposed to be involved
more in diabetic macrovascular dysfunction [30].
(c) Mechanisms related to overproduction of growth
factors and cytokines
Diabetes has been established to be associated with
overproduction of growth factors and cytokines which have
an influence on endothelial cell function. Hyperglycemia
is known to contribute to this effect by inducing
increased synthesis of these factors in different types of
cells [15, 27, 41]. Among others, the mechanisms for this
effect involve hyperglycemia-induced PKC activation,
AGE production and cytokine activation of endothelia
cells. Hyperglycemia being a common factor, such processes
can take place in both type 1 and type 2 diabetes.
Overproduction of growth factors has been implicated as
a link between diabetes and proliferation of endothelial cells
and vascular smooth muscle cells, possibly promoting
neovascularization [15, 27, 41]. Among the growth factors
that play important roles in diabetes complications, TGF-β1
and vascular endothelial growth factor (VEGF) have greater
influence on endothelial cells. The receptors for both
hormones are expressed in endothelial cells [15, 27]. Both
growth factors regulate multiple cellular functions in
different tissues. For TGF-β1, these include cell growth,
cell death/apoptosis, cellular differentiation and extracellular
matrix protein synthesis. Similarly, VEGF stimulates cell
differentiation, survival, migration, and proliferation, tubulo-
genesis and vascular permeability [15, 27]. However,
although the levels of these growth factors have been shown
to increase in animal models of diabetes, the temporal
sequence is not well defined, implying that the roles of
growth factors in diabetes require further investigation.
Although certain cytokines appear to play significant
roles in endothelial functions, many cytokines produce
effects to which endothelial cells respond variably. In
short, in the vasculature, inflammatory cytokines enhance
vascular permeability, alter vasoregulatory responses,
increase leukocyte adhesion to endothelium, facilitate
procoagulant activity, and regulate gene expression in
endothelial cells, among other effects [15, 27]. Of the




















Fig. 5 Insulin signaling pathways in endothelial cells. The PI3K/Akt
branch regulates NO production in endothelial cells and vasodilation
in vascular smooth muscle cells. The MAPK branch controls secretion
of endothelin-1 in the endothelium, and also regulates growth and
mitogenesis. Under normal conditions, there is an optimum balance
between these pathways. Abbreviations: IRS-1: insulin receptor
substrate protein-1; PI3K: phosphatidylinositol-3-kinase; PDK-1:
phospho-3’-phosphoinositide-dependent kinase-1; NO: nitric oxide;
eNOS: NO synthase-type III; MAPK: mitogen-activated protein
kinase; Et-1: endothelin-1; VSMC: vascular smooth muscle cell
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link between insulin resistance, diabetes, and endothelial
dysfunction. In view of the association between obesity
and insulin resistance, increased expression of TNF-α
(and others) in human obesity supports the hypothesis that
its elevation induces insulin resistance. TNF-α also
induces the synthesis of other cytokines, such as interleukin
(IL)-1, which in turn regulates the expression of c-reactive
protein (CRP), an important downstream marker of inflam-
mation [15, 27]. These mediators, alone or in concert with
each others, contribute to artherothrombosis by altering
endothelial function.
More recently a strong association has been found
between obesity and insulin resistance/type 2 diabetes.
Accordingly, endothelial dysfunction occurring in obese
subjects or animal models of obesity can be related to
insulin resistance/type 2 diabetes, although obesity can also
be an independent risk factor for this dysfunction and
associated disorders. This relationship is believed to be, at
least in part, the result of overproduction of chemical
mediators from adipose tissue in the obese. Evidence has
been accumulating that visceral adipose tissue is specially a
highly active endocrine organ that releases a variety of
substances, including certain hormones, cytokines and
enzymes that are capable of attenuating insulin sensitivity
[32, 40, 42]. Of these products, cytokines (for example,
TNF-α, IL-6, PAI-1) and adipokines (for example,
adiponectin, lepin) have been proposed to play a role
in inflammation, insulin resistance and vascular disease
[27, 32, 40]. Studies have shown that while some of these
mediators are protective, others are associated with various
adverse effects, as noted earlier. On balance, however,
visceral obesity gives rise to insulin resistance and endothe-
lial dysfunction primarily through a cascade of secreted
proinflammatory substances, such as cytokines and CRP.
Furthermore, insulin resistance by causing hyperglycemia,
may perpetuate inflammation via augmented oxidative stress
[30, 32, 40].
Assessment of endothelial function/dysfunction in humans
Since the initial report by Furchgott and Zawadzki [19]
revealing the role of the endothelium in vasorelaxation,
the function of the endothelium has been a focus in the
study of vascular disease. With the initial understanding
that derangement in NO formation contributes to the
development of artherosclerosis, various techniques for
assessing endothelial function/dysfunction in humans in
relation to the release of NO in coronary circulation as
well as in the systemic circulation have been developed.
Most of the endothelial functional tests performed are
meant to evaluate abnormalities in the regulation of the
lumen of blood vessels [22, 43–46]. However, this
approach may not necessarily be reflective of the function
of the endothelium at a given time point because (a) the
lumen of blood vessels can also be influenced by factors
other than the endothelium, such as smooth muscle
alterations independent of the endothelium and (b)
endothelial cells may affect one or more functions in
the vasculature, either simultaneously or in a temporal
sequence, and as such cannot always be considered a
single and discrete functional entity [22, 43, 45]. Thus,
with the assessment of the above parameter (reflection of
lumen size), it is not always possible to reliably define the
status of the endothelium. This requires the need for
developing techniques that can be more precise, selective
and sensitive for measuring endothelial function.
While the current methods for assessing endothelial
function in humans are used alone in most cases, sometimes
they are complemented by measurements of plasma
concentrations of biomarkers (e.g., nitrite assays), or an
index of the structure of the vessel such as assessment of
carotid intima media thickness [43–54]. The following is a
brief description of the methods that are commonly
utilized to measure endothelial function/dysfunction in
humans as an outcome of endothelial cell activity.
Use of plethysmography
This method is based on strain-gauge venous impedance
plethysmography for studying endothelium-dependent as
well as independent vasodilatation in the peripheral
circulation [22, 43, 45, 46]. It is especially designed for
mapping dose-response relationships of stimulators and
inhibitors of endothelial cell activity. This technique
often uses direct infusion (by arterial cannulation) of
acetylcholine, or other muscarinic receptor agonists (as a
selective activator of endothelial cells) in the brachial
artery and determines the vasodilator responses in the
forearm resistance vessels. Sodium nitroprusside is
usually administered as a control agent in order to assess
endothelium-independent vasodilatation. The determination
of changes in blood flow (reflective of lumen size),
contributed by the whole limb portion indicates a measure
of endothelial function. However, the invasive nature of the
technique limits its repeatability and prohibits its use in
larger studies. In addition, the results are also difficult to
standardize because resistance vessel tone is variable, in
addition to the general problems mentioned above in
connection to the measurement of lumen size [22, 43–46].
Use of ultrasound and doppler
In coronary circulation, non-invasive methods for assessing
endothelial function, including doppler echocardiography,
positron emission tomography and phase-contrast magnetic
resonance imaging, were described before the development
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of most of the currently used methods [43, 44, 46, 47].
However, in view of technical difficulties and high-costs
associated with these techniques, their uses have remained
very limited. Subsequently, quantitative coronary angiography
with an intra-coronary ultrasound and doppler transducer has
been developed and used more often to assess endothelial
function in the coronary circulation [22, 43–47]. By a graded
administration of acetylcholine and sodium nitroprusside,
endothelium-dependent and independent vasodilatation,
respectively, can be quantified using this approach.
Nonetheless, in addition to being invasive, this technique
is also technically complicated for routine application. This
leads to the emergence of a simpler and a noninvasive
method based on flow-mediated vasodilatation (FMD) in
brachial artery, which is more suitable for repeated studies and
for evaluating large groups of patients [22, 43, 45, 47, 48].
This method uses ultrasound for detection of changes in
artery diameter (lumen) and blood flow. Flow-mediated
vasodilatation thus measured in brachial artery has been
found to correlate well with endothelial function in the
coronary circulation [49]. Because of the above advantages,
this method has been widely used, and in fact, it is
considered to represent the gold standard for clinical
research on conduit artery endothelial biology [50].
Flow-mediated vasodilatation is based on the theory of
shear stress, whereby a short period (for example, 5 min)
of arterial occlusion increases flow in the artery. This
procedure is believed to induce the endothelium to release
NO with subsequent vasodilatation. Nitroglycerin (or
another nitrate) is administered sublingually/orally to
evaluate endothelium-independent vasorelaxant responses.
In shear stress, no specific receptor signaling pathway has
been reported to be activated or inhibited. Therefore, the
precise mechanisms for the detection of shear stress and
the subsequent signal transduction to modulate vasomotor
tone are not fully understood [51].
Brachial artery FMD has been studied widely in clinical
research because, among others, it enables serial assessment
of young subjects, and also permits testing of lifestyle and
pharmacological interventions on the endothelium at an
early stage of a disease (i.e., when the disease process is
most likely to be reversed) [22, 43, 46]. However, the
equipments used in this technique are still expensive and
the procedures involved are also technically demanding,
although the protocol can be reliably standardized to yield
reproducible results that correlate with coronary vascular
endothelial function [43, 46].
Circulating endothelial markers relevant to diabetes
In view of the significance of assessing the status of the
endothelium in vasculopathy and the limitations of the
above techniques, more recent efforts have been directed
towards exploring other approaches of evaluation based on
measurement of circulating endothelial markers. The
advantages of measuring such circulating indicators may
include (a) simplicity of quantification with current immu-
nological techniques for most of them, (b) the release of
most of the biomarkers specifically from the vascular
endothelium and the possibility of providing information
on the status of the endothelium directly and/or (c) their
involvement (directly or indirectly) in the function or
regulation of endothelial cells. However, it is noteworthy
that the usefulness of this approach has not yet been fully
verified for clinical applications and some of the procedures
involved may also require delicate conditions of sampling
and/or analysis [43, 44, 46]. Nonetheless, there appears to
be a general consensus that circulating endothelial
biomarkers have the potential to be used for routine
clinical testing of endothelial dysfunction in patients with
possible vascular disorders. Thus, we will describe some
biomarkers which are believed to be relevant for assessing
endothelial function/dysfunction in diabetes (and other
similar conditions) (Fig. 6). Except endothelial progenitor


















Fig. 6 Major endothelial-derived circulating biomarkers. While vWF,
sTM, ADMA, EMP, sE-selectin, tPA and endotheline-1 are released
into the circulation specifically by endothelial cells, the other
biomarkers shown are also released by other types of cells, making
assay of the latter less specific to precisely reflect the status of the
endothelium. In addition, the assay method available for endothelin-1
is not sensitive enough to reveal relatively subtle changes in the
endothelium. Abbreviations: NO: nitric oxide; eNOS: NO synthase-
type III; NF-kB: nuclear factor kB; EMP: endothelial microparticle;
TM: thrombomodulin; sTM: soluble TM; vWF: von Willebrand
factor; WPB: Weibel-Palade body; tPA: tissue plasminogen activator;
ADMA: asymmetric dimethylarginine; sVCAM: soluble vascular cell
adhesion molecule-1; sICAM: soluble intracellular adhesion molecule
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of being released specifically from the vascular endothelium.
Endothelial progenitor cells are also closely associated
with the endothelium in a different way, as detailed
below. It should be noted that there are several other
circulating biomarkers which are not specific to the
endothelium and/or their assays are less sensitive to
detect subtle changes in the endothelium. Examples of
such biomarkers include P-selectin, adhesion molecules
such as vascular cell adhesion molecule-1 (VCAM-1)
and intercellular adhesion molecule-1 (ICAM-1),
endothelin-1 and NO/nitrite [43–47, 52] (Fig. 6).
Von Willebrand factor
Von Willebrand factor (vWF) is a glycoprotein released
from the endothelium [43, 52]. It is a large multimeric
structure consisting of over 80 subunits of 250 kDa each.
Its presence in the circulatory system is important for
platelet aggregation and adhesion and for factor VII
survival [43, 52]. Only the large multimers are believed to
be functional. As such, vWF plays a vital role in mediating
platelet adhesion to damaged arterial walls, thereby causing
localized blood clots or thrombus formation.
Von Willebrand factor is produced and stored in
endothelial Weibel-Palade bodies and secreted into blood
upon endothelial cell injury (Fig. 6). It is considered a gold
standard in the measurement of endothelial damage. Its
plasma level has been shown to increase in vascular disease
such as that associated with diabetes or insulin resistance
[43, 52]. Plasma vWF can be determined by enzyme-linked
immunosorbent assay (ELISA) kit which makes
use of a monoclonal antibody.
Soluble thrombomodulin
Thrombomodulin (TM) (CD141/BDCA-3) is a membrane
protein expressed on the surface of endothelial cells [43, 52].
It has a molecular mass of 74 KDa, consisting of a single
chain with five distinct domains. It serves as a cofactor for
protein C activation in anticoagulant pathway involving
thrombin.
Thrombomodulin, like vWF, can be released from
injured endothelial cells, and its soluble form (soluble
thrombomodulin, sTM) has been demonstrated to be a
specific biomarker of endothelial cell injury (Fig. 6).
Plasma sTM concentration can be measured reliably by
ELISA kits [43, 52].
Soluble E-selectin
E-selectin is a member of the selectin family adhesion
molecules, which is specifically expressed on the surface
of cytokine-activated endothelial cells [43, 44, 52]. In
this regard, it was observed that maximal expression of
E-selectin on the surface of human umbilical vein
endothelial cells (HUVECs) occurred 6 h after stimulation
by TNF-α or IL-1 and the level remained sustained for at
least 24 h [43, 44]. E-selectin plays an important part in
inflammation by enabling the recruitment of leukocytes to
the site of cell injury.
A circulating or soluble form of E-selectin (sE-selectin) is
released from endothelial cells by enzymatic cleavage or as a
result of shedding of damaged or activated cells [43, 44, 52]
(Fig. 6). It has been shown that the plasma concentration of
sE-selectin is correlated to its expression on the surface of
HUVECs [43, 44]. Hence, plasma level of sE-selectin has
been proposed to serve as a marker of endothelial cell
damage and/or activation. The role of E-selectin in vascular
disease has been extensively investigated in recent years
and it appears that there is the possibility of developing
an E-selectin assay system for routine clinical application
[43, 44]. Soluble E-selectin in the plasma can be detected
by a sensitive ELISA kit [43, 44].
Asymmetric dimethylarginine
Asymmetric dimethylarginine (ADMA) is a molecule
considered to be an endogenous inhibitor of eNOS, thereby
reducing the level of endothelial NO [43, 44, 46, 53]. It is a
metabolic product of protein modifications and is closely
related to L-arginine. Following its formation, ADMA
migrates into the extracellular space and then into the
blood (Fig. 6). Evidence is also available that the molecule
may cause eNOS uncoupling, thereby switching eNOS
from a NO- to superoxide-generating enzyme [43–46, 53].
Elevated plasma ADMA levels have been associated
with many cardiovascular risk factors including diabetes
and insulin resistance [43–46, 53]. A direct correlation has
also been observed between the concentration of ADMA
and the severity of cardiovascular diseases. For instance,
the level of ADMA was shown to be doubled when
endothelial function was further impaired in diabetic
patients after a high-fat meal [43–46, 53]. As a result, in
recent years, considerable attention has been placed on
ADMA as a diagnostic indicator and as a mediator of
endothelial dysfunction. Asymmetric dimethylarginine
(ADMA) can be measured by HPLC [43–46, 53].
Tissue plasminogen activator
Tissue plasminogen activator (tPA) is a protein (serine
protease) released by vascular endothelial cells [43, 44]. It
is involved in breakdown of blood clots by catalyzing the
conversion of plasminogen to plasmin. It also plays a role
in cell migration and tissue remodeling. Being specifically
released by endothelial cells, circulating tPA has been
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suggested to serve as a suitable biomarker of endothelial
cells (Fig. 6). It has been shown to be elevated in
hypercholestrolaemia and subclinical conditions of stroke,
myocardial infarction and atheosclerososis [43, 44]. Studies
also indicate that the production of tPA is higher in
atheromatous arteries than in normal blood vessels [43, 44].
From these observations, it has been suggested that
increased tPA levels may reflect excessive endothelial cell
activation and/or damage. However, as yet, no reports have
been published regarding the role tPA in diabetic vascular
disease.
Circulating tPA levels have been demonstrated to
increase rapidly with local adrenergic or cholinergic
receptor stimulation [54]. This suggests that assessment of
tPA release after adrenergic or cholinergic receptor
stimulation may be a valuable tool for evaluating endothelial
function.
Tissue plasminogen activator (tPA) can be measured by
using ELISA or by measuring its activity, both assays
providing closely similar results [43].
Endothelial microparticles
Endothelial microparticles (EMPs) have recently been
identified to be circulating phospholipids-rich submicron
vesicles that are released from membranes of endothelial
cells as a consequence of activating or injurious external
stimuli, although some studies suggest that similar particles
are also released by platelets and T lymphocytes under
certain conditions [43, 46, 52, 55, 56] (Fig. 6). These
microparticles consist of plasma membrane structures
containing receptors and other cell surface molecules which
enable the identification of their endothelial origin. This
allows them to be distinguished from microparticles from
other cell types, if present. Although circulating EMPs can
be found in the blood of normal subjects, increased number
of the microparticles have been measured in individuals
with diseases affecting blood vessels including diabetes
[43, 46, 52, 55, 56]. As a result, EMPs have gained greater
considerations to be utilized as an index of changes in
endothelial function/structure for such disease states. Also,
endothelial changes that may be correlated with levels of
circulating EMPs can serve to indicate the severity of the
disease per se.
With regard to diabetes, in a number of studies, increased
release of EMPs has been shown along with reductions in
endothelium-dependent vasorelaxation and NO production
[55, 56]. Corroborating with this observation, a correlation
has also been seen between EMPs and reduced FMD of
arteries in diabetic patients with renal failure. In another
group of patients with diabetes, augmented circulating EMPs
was measured together with an increase in ICAM-1 [55, 56].
From these studies, it appears that the more severe the
diabetes state is, the greater the amount of EMP in the
circulation, both of which correlate with the degree of
dysfunction of the endothelium.
More recent investigations have revealed that EMPs
impair endothelium-dependent relaxation and NO production
in the rat aorta [55, 56]. This effect may be related to an
increase in superoxide anion production, which might reduce
the bioavailability of NO. Therefore, microparticles of
endothelial origin may reflect cellular injury in this way
too, and, as such, may serve as circulating markers for
endothelial/vascular dysfunction that are easily measured in
the blood [55, 56].
Endothelial microparticles can be assayed by analyzing
the expression of CD31+/CD41-, CD144 and CD62e+ on
circulating cell surface by flow cytometry [55, 56]. Among
these surface markers, CD62e+ is more specific to
endothelial cells; the expression of this marker is enhanced
by cytokine. Phenotype analysis of EMPs is based on size
characterization and fluorescence measurement, which
ultimately enables determination of EMP levels [55, 56].
Another less widely utilized method is functional assay
performed using the pro-coagulant property of EMPs
[55, 56]. However, due to lack of standardization, the
measurement of EMPs by both methods remains a
technical challenge.
Circulating endothelial cells
Circulating endothelial cells (CEC) are mature cells
expressing the membrane glycoproteins CD146, CD31
and CD144 [46, 52, 56, 57]. They are rarely found in the
blood of healthy subjects but are elevated in disease
conditions associated with cardiovascular and inflammatory
disorders. They present a heterogeneous size ranging from
10 to 50 micron. These cells are negative for leukocyte
markers and, unlike EPCs, do not express immature
markers such as CD133 and do not rise with high
proliferative potential [56, 57]. Circulating endothelial cells
(CEC) may arise from damaged endothelium, although the
mechanisms of endothelial cell detachment are multiple and
not exclusive. Denudation of the vessels may be triggered
by mechanical injury, defective adhesion, protease- or
cytokine-mediated detachment or activation of apoptosis,
among other possible reasons. A major problem associated
with CEC quantification is their low number in blood (i.e.,
approximately one per one million nucleated cells). To
circumvent this limitation, CECs first have to be enriched
(using CD146 coated magnetic microbeads) and then
phenotyped using monoclonal antibodies to cell surface
glycoproteins [52, 56, 57]. This process is known as
immuno-magnetic separation (IMS) assay, which has now
become a consensus protocol for CEC quantification.
Alternative method for CEC counting includes flow
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cytometry; however, in most cases, this method provides
inconsistent results relative to the IMS assay.
The use of CECs as a biomarker of vascular endothelial
dysfunction and the associated risk factors such as diabetes
and hypertension has recently been reviewed [56, 57]. In
fact, an inverse correlation was found between CEC levels
and FMD, indicating a positive relationship between
endothelial dysfunction and increased CEC number. A
positive correlation was also shown between CECs and
vWF but not between CECs and sE-selectin, suggesting
that CECs may reflect endothelial damage rather than
endothelial activation [56, 57]. Furthermore, CECs levels
have been observed to positively relate to the degree of
coronary syndrome and peripheral arterial disease. Besides
their role in diagnosis, CECs have also been proposed as a
novel prognostic indicator since raised CEC levels could
independently predict both death and adverse cardiovascular
events before they could occur [52, 56, 57].
Circulating endothelial progenitor cells
Recently, endothelial progenitor cells (EPCs) released
from bone marrow into the circulation have been found
to be critical for maintenance and repair of the vascular
endothelium [58] (Fig. 7). In this process, EPCs undergo
differentiation into mature ECs following recruitment. It is
therefore plausible that endothelial dysfunction that occurs
in diabetes may be linked to alterations of EPCs. This
observation has been explored to find out if EPCs can be
used as a viable biomarker for risk assessment or prediction of
vascular disorders and target organ deficiencies in diabetes
(and other disease) affecting the vasculature [44, 52, 53, 56]
(Fig. 7).
Endothelial progenitor cells (EPCs) are a group of
heterogeneous bone marrow-originated cells that can be
characterized by expression of surface markers, including
CD34+, DC133+ and vascular endothelial growth receptor-2,
by acetylated low density lipoprotein (LDL) uptake and by
lecitin binding [59–61]. With cultivation of mononuclear
cells (MNCs) from human peripheral blood, these cells
attach and develop an endothelium-like phenotype in blood
vessels. After being transported, the cells can incorporate
into sites of active neovascularization.
Cardiovascular risk factors, including diabetes, that
cause endothelial dysfunction, have been shown to be
associated with decreased number and functional ability of
circulating EPCs [59–61]. Such an inverse association
between circulating EPCs and endothelial dysfunction has
been observed in human patients as well as animal models
of both type 1 and type 2 diabetes (58–60). In EPC colonies
from culture of MNCs, diabetes and hyperglycemia-induced
functional impairments have been reported to be mediated via
mechanisms involving chemokines (e.g., growth factors,
stromal-derived factor (SDF-1), granulocyte-monocyte
stimulating factor (GM-SCF)), eNOS/NO, and matrix
metalloproteinase-9 (MMP-9) [59–63]. From these and
other related findings, low circulating EPCs have been
proposed to represent a useful indicator for future
cardiovascular events. Other studies have also related
impairment of EPC functionality to cardiovascular disorders
[59–61]. It is noteworthy that most studies on EPCs reported
to date in relation to diabetes have been conducted under
conditions favoring or associated with overt vascular
endothelial dysfunction. This implies that the assessment of
the effects of diabetes/prediabetes on circulating EPCs prior
to the development of detectable endothelial dysfunction
remains to be performed. Data from such studies can help to
determine whether or not predictions of future cardiovascular
outcomes are possible based on the status of EPCs.
A number of chemokines and related factors appear to
regulate the release and function of EPCs [59–61]. Vascular
endothelial growth factor (VEGF), which regulates vasculo-
genesis and angiogenesis, is involved in the mobilization of
EPCs from bone marrow. Nitric oxide, in addition to
modulating various aspects of endothelial function has
been shown to have a significant role in the activities
of EPCs [60]. Impaired MMP-9 activity has been
demonstrated to contribute to reduced EPC mobilization in
such cardiovascular conditions as post-myocardial infarction
[61], but this has not been determined for blood vessels.
Furthermore, SDF-1 has been reported to be involved in the
pathophysiology of EPCs and promotion of angiogenesis by
enhancing EPC release and its incorporation into new















Fig. 7 Proposed role of circulating EPCs in endothelial function/
dysfunction and disorder of the vasculature in diabetes. EPCs released
from bone marrow are involved in the repair of endothelial cells under
normal conditions and their levels in the circulation have been shown
to decrease significantly when there is impairment or damage to the
endothelium. Abbreviations: EPCs: endothelial progenitor cells; ECs:
endothelial cells
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(GM-SCF) is another substance with significant ability to
stimulate the mobilization of EPCs from bone marrow,
thereby leading to homage to regions of vascular damage for
regeneration [59–63]. Thus, the consideration of the above
factors is important when studying the role of EPCs in
relation to endothelial function/dysfunction in diabetes
and other diseases having an effect on the vasculature/
endothelium.
Circulating EPCs can be quantified in whole blood using
the technique of flow cytometry. For this, MNCs, (identified
by CD34/KDR and CD133/KDR double positive cells) are
isolated using density-gradient centrifugation followed by
flow cytometry assay [66]. These cells can also be studied
directly for their proliferating property. The functional
abilities of EPCs can be determined in some detail ex-vivo
using expanded cell culture by the application of different
assay methods. For culturing, the MNCs are usually
separated in histopaque-1083 density gradient medium, and
then expanded using appropriate media and conditions [66].
The number of cell colonies obtained from a sufficient
number of wells is determined manually under a microscope
by a trained observer. Commonly performed assays to
evaluate the functionalities of EPCs include chemotaxis,
cell proliferation, eNOS activity/expression, senescence-
associated β-galactosidase activity, apoptosis/cell survival
rate and matrigel tube formation [62, 63, 67–69]. The
measurement of these parameters enables to determine if
there is a correlation between the number and functions of
EPCs and the status of the endothelium in health and
disease. If a correlation is established using accessible
methodologies, the opportunity exists for EPCs to be used
routinely as an index of endothelial dysfunction associated
with vascular diseases.
Conclusion
Diabetes is associated with vascular complications, which
contribute to the death of as high as 80% of diabetic patients.
Endothelial dysfunction plays a critical and an initiating role
in vascular disorders in both type 1 and type 2 diabetes and
insulin resistance/prediabetes. Assessing the status of the
endothelium can serve as a valuable diagnostic and prognostic
tool for vascular disease in diabetes. Endothelial function/
dysfunction has been assessed in humans using techniques
utilizing the measurement of the functional consequences of
endothelial activity (ie., relaxation/lumen size changes of
blood vessels). The commonly utilized techniques in this
regard apply plethysmography, ultrasound and/or doppler to
measure blood flow or lumen size in coronary arteries and
peripheral blood vessels (e. g., brachial arteries). While these
techniques are used primarily for research purposes, some of
them appear to be clinically relevant only for a limited scope
of evaluation. Certain limitations associated to the methods,
particularly as related to technical difficulties and costs, have
precluded their routine clinical application.
Recently, a number of endothelial-derived circulating
markers have been found to more directly reflect the status
of the endothelium. These include vWF, sTM, sE-selectin,
ADMA, tPA and EMPs. While the relative significance of
each substance (or their combinations) for endothelial
evaluation is undefined presently, in most cases, these
biomarkers provide good indications of endothelial damage/
activation, as it occurs in disease states, such as diabetes,
which adversely affect the vasculature. Nonetheless, the
measurement of these circulating indicators for diagnosis
and/or prognosis of endothelial dysfunction and the associated
vascular disorders has not yet been established for
routine clinical use. Other indicators of endothelial
function/dysfunction are CECs and circulating EPCs,
which have the potential to offer additional information
on the status of the endothelium. However, only very few
studies have investigated the clinical application of these
cellular biomarkers, indicating limitation of information
on their usefulness for diagnostic and/or prognostic
purposes. Taken together, currently, the issue of circulating
endothelial markers is an area of intense research interest
with the potential to lead to the development of clinically
relevant assessment techniques. It is hoped that as more
data become available, the improved measurement of
circulating endothelial indicators will make it possible to
obtain valuable diagnostic and prognostic information on
vascular events in diabetes and related conditions for
routine clinical testing.
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